How Phase 2 Cancer Trial Data At Tyra Biosciences (TYRA) Has Changed Its Investment Story
Wedbush Maintains Outperform on Tyra Biosciences, Raises Price Target to $57
HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $27
Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
Tyra Biosciences Q3 EPS $(0.74) Misses $(0.69) Estimate
Tyra Biosciences to Participate in Upcoming Investor Conferences
Tyra Biosciences (TYRA) Stock Looks Rich Against Its Book Value
Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value
Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks
Oppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40
HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $29
Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?
Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Tyra Biosciences Prices Underwritten Offering Of 9,079,000 Shares And Warrants At $22.03 Per Unit
Tyra Biosciences Files Prospectus To Sell Mixed Securities Shelf Of Undisclosed Amount
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC - Slideshow
Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $53 Price Target
HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $30
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.